[{"id":"1c21f072-efd7-4fab-8b11-da62fb5de78c","acronym":"DUBHE-L-303","url":"https://clinicaltrials.gov/study/NCT05690945","created_at":"2023-01-19T14:59:48.148Z","updated_at":"2024-07-02T16:35:57.383Z","phase":"Phase 3","brief_title":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05690945 - DUBHE-L-303","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Tevimbra (tislelizumab-jsgr) • Qibeian (iparomlimab/tuvonralimab) • BGB-108"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 650","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/23/2025","primary_completion_date":" 06/23/2025","study_txt":" Completion: 06/23/2025","study_completion_date":" 06/23/2025","last_update_posted":"2023-01-19"}]